On 11/9/23, Supernus Pharmaceuticals Inc (NASDAQ: SUPN) stock enjoyed a major increase of 11.1%, closing at $26.14. Relative to the market the stock has been weak over the last nine months but has risen 9.3% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, SUPN is expected to continue to be a modest Value Builder.
Supernus Pharmaceuticals has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Supernus Pharmaceuticals has a slightly positive Appreciation Score of 62 but a very low Power Rating of 12, leading to the Negative Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment